Inhibitor Therapeutics, Inc. Cash and Restricted Cash
Inhibitor Therapeutics, Inc. (INTI) had Cash and Restricted Cash of $515.76 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $515.76K.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.29M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.38M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.98M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $515.76K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $1.29M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.38M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $2.98M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.74M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $4.32M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $5.61M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $6.38M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $7.10M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $7.68M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $8.84M 10-K · filed 2026-03-26 |
| 2023-09-30 | $9.54M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $10.10M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $10.78M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $11.95M 10-K · filed 2025-03-28 |
| 2022-09-30 | $53.06K 10-Q · filed 2023-11-13 |
| 2022-06-30 | $24.95K 10-Q · filed 2023-08-11 |
| 2022-03-31 | $36.44K 10-Q · filed 2023-05-15 |
| 2021-12-31 | $30.63K 10-K · filed 2024-03-29 |
| 2021-09-30 | $53.29K 10-Q · filed 2022-11-14 |
| 2021-06-30 | $93.72K 10-Q · filed 2022-08-12 |
| 2021-03-31 | $84.19K 10-Q · filed 2022-05-13 |
| 2020-12-31 | $75.06K 10-K · filed 2023-03-31 |